Baylor Research Institute

Schering Corporation

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-Hopitaux De Paris

Université Paris Est Creteil Val De Marne

Sandra M Zurawski

Gerard Zurawski

SangKon Oh

Jacques F Banchereau

Anne-Laure Flamar

Eynav Klechevsky

Dapeng Li

Hyemee Joo

Yves Levy

Peter Klucar

Keiko Akagawa

Daniel M Gorman

Terrill K McClanahan

Joseph H Phillips

Donna M Rennick

Lewis L Lanier

Yong-Jun Liu

Gosse Jan Adema

Patrick Blanco

Hideki Ueno

Linde Meyaard

Haruyuki Fujita

Shino Hanabuchi

Stephen D Hurst

Timothy R Mosmann

Monica Montes

Keith D Brown

Ling Ni

Gerald Zurawski

Holly Mead

Amanda Cobb

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

Vaccines against HPV and HPV-related diseases

The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)

Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.

Methods and compositions for treating autoimmune and inflammatory conditions

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Fusion proteins comprising an anti-CD40 antibody and cancer antigens

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Nucleic acids encoding anti-CD40 antibodies

Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

Methods and compositions for treating and preventing HIV

Anti-CD40 antibodies

Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-&#x3b1; and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell&#x2014;(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

Antagonistic anti-OX40L antibodies and methods of their use

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

Growing community of inventors

Redwood City, CA, United States of America

Sandra M Zurawski